SCHEMBL6008516

SCHEMBL6008516

CCCCCC=CCNC=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.61
TRPV1 Q8NER1 2/20 0.61
ADH1B P00325 2/20 0.52
ADH1C P00326 2/20 0.52
ADH1A P07327 2/20 0.52
ADH7 P40394 2/20 0.52
EPHX1 P07099 1/20 0.52
ADH4 P08319 1/20 0.52
TSHR P16473 2/20 0.50
ALDH1A1 P00352 1/20 0.47
TERT O14746 3/20 0.44
PTPN1 P18031 3/20 0.44
CYP1A2 P05177 2/20 0.44
MAPT P10636 2/20 0.44
CYP2C19 P33261 2/20 0.44
BLM P54132 2/20 0.44
HSD17B10 Q99714 2/20 0.44
FABP4 P15090 2/20 0.44
PPARG P37231 2/20 0.44
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17715326 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL17715336 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL17715337 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL10011618 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL17715335 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL16661028 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL17715338 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL17715329 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL10013073 0.98 FAAH (0.65) FAAHTRPV1ADH1BADH1CADH1A
SCHEMBL6008369 0.93 FAAH (0.52) FAAHTRPV1ADH1BADH1CADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 FAAH 3350/4885TRPV1 588/4885ADH1B 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.